Xenetic Biosciences Files 8-K: Material Agreement & Other Events

TL;DR

Xenetic Biosciences signed a big deal and filed an 8-K. Details TBD.

AI Summary

On October 10, 2025, Xenetic Biosciences, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this 8-K filing. The specific details of the agreement and financial information are not provided in this excerpt.

Why It Matters

This filing indicates significant corporate activity, including a material definitive agreement and the submission of financial statements, which could impact the company's future operations and stock performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could be positive or negative, and the lack of specific details warrants a medium risk assessment.

Key Players & Entities

• Xenetic Biosciences, Inc. (company) — Registrant
• October 10, 2025 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 001-37937 (identifier) — Commission File Number
• 45-2952962 (identifier) — IRS Employer Identification No.
• 945 Concord Street, Framingham, Massachusetts 01701 (address) — Business and Mail Address

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share XBIO The Nasdaq
• $6.12 — er share, at a public offering price of $6.12 per share. The Offering is expected to
• $3.9 million — from the Offering will be approximately $3.9 million after deducting underwriting discounts

Filing Documents

• xenetic_8k.htm (8-K) — 33KB
• xenetic_ex0101.htm (EX-1.1) — 185KB
• xenetic_ex0501.htm (EX-5.1) — 12KB
• xenetic_ex9901.htm (EX-99.1) — 9KB
• image_085.jpg (GRAPHIC) — 4KB
• 0001683168-25-007528.txt ( ) — 455KB
• xbio-20251010.xsd (EX-101.SCH) — 3KB
• xbio-20251010_lab.xml (EX-101.LAB) — 33KB
• xbio-20251010_pre.xml (EX-101.PRE) — 22KB
• xenetic_8k_htm.xml (XML) — 3KB

01

Item 1.01. Entry into a Material Definitive Agreement. On October 10, 2025, Xenetic Biosciences, Inc., a Nevada corporation (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Canaccord Genuity LLC as representative of the several underwriters named therein, relating to an underwritten public offering (the "Offering") of 735,000 shares (the "Shares") of the Company's common stock, par value $0.001 per share, at a public offering price of $6.12 per share. The Offering is expected to close on October 14, 2024. The Company estimates that the net proceeds from the Offering will be approximately $3.9 million after deducting underwriting discounts and commissions and other estimated offering expenses to be paid by the Company. The Company intends to use the net proceeds (after the payment of any offering expenses and/or underwriting discounts and commissions) from the sale of the Shares for working capital and other general corporate purposes, as well as for the advancement of the DNase technology. The Offering was made pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-282756), filed on October 21, 2024, that was declared effective by the Securities and Exchange Commission on November 1, 2024, and a related base prospectus and prospectus supplement thereunder. Pursuant to the terms of the Underwriting Agreement, the Company has agreed to certain restrictions on the issuance and sale of its Common Stock and securities convertible into shares of Common Stock during the 60-day period following the date of the Underwriting Agreement. The Underwriting Agreement contains customary representations and warranties, conditions to closing, termination provisions, and indemnification obligations of the Company, including for liabilities under the Securities Act of 1933, as amended. A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated he

01

Item 8.01. Other Events. The Information in Item 1.01 above is hereby incorporated by reference into this Item 8.01. On October 10, 2025, the Company issued a press release announcing that it had priced the Offering. A copy of the press release is attached as Exhibit 99.1 hereto, and is incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement dated October 10, 2025, between Xenetic Biosciences, Inc. and Canaccord Genuity LLC 5.1 Opinion of Westward Law, LLC 23.1 Consent of Westward Law, LLC (contained in Exhibit 5.1). 99.1 Press Release, dated October 10, 2020 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XENETIC BIOSCIENCES, INC. By: /s/ James Parslow Date: October 14, 2025 Name: James Parslow Title: Interim Chief Financial Officer and Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR